HomeDiscoveryPipeline

Pipeline

L’attuale portfolio delle molecole di Nerviano Medical Sciences comprende composti antitumorali in fase clinica o in avanzato stadio di sviluppo preclinico, oltre ai progetti di ricerca.
Diversi programmi sono condotti nell'ambito di alleanze strategiche.

ENCORAFENIB
B-RAF melanoma combo
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENCORAFENIB
B-RAF CRC combo
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
ROS NSCLC
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
TRK solid tumors
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ONVANSERTIB
AML & solid tumor combo
PRECLINICAL PHASE I PHASE II PHASE III
63% PHASE II
MILCICLIB
HCC
PRECLINICAL PHASE I PHASE II PHASE III
63% PHASE II
 
PRECLINICAL PHASE I PHASE II PHASE III
A602
(Danusertib)
PRECLINICAL PHASE I PHASE II PHASE III
50% PHASE I
M912 SA
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
M801 SA
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
M801 combo
PRECLINICAL PHASE I PHASE II PHASE III
20% PRECLINICAL
P707 SA
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
P707 combo
PRECLINICAL PHASE I PHASE II PHASE III
20% PRECLINICAL
P807
PRECLINICAL PHASE I PHASE II PHASE III
20% PRECLINICAL
Early Pipeline
PRECLINICAL PHASE I PHASE II PHASE III
13% PRECLINICAL